FDA Publishes BsUFA III Commitment Letter Ahead Of 2022 Renewal
Biosimilar Supplement Review Goals Aim To Speed Approvals
Following months of negotiations with industry and stakeholders, the FDA has released the commitment letter for the third iteration of its five-year Biosimilar User Fee Amendments program, marking another step ahead of its reauthorization.
